ASAQ to treat malaria = Fixed dose combination of Artesunate + Amodiaquine

  • Launched in 2007
  • The concrete results of an innovative partnership between DNDi and Sanofi
  • Meets the latest WHO guidelines for malaria treatment in Africa
  • Simple regimen: Once daily fixed dose combination for 3 days
  • Available at only 0.5$ for children, 1$ for adults
  • Meets the highest standard of quality
  • Made in the South for use in the South: ASAQ is produced in Morocco
  • Available under the name Artesunate-Amodiaquine Winthrop (ASAQ) for public market and Coarsucam for private market
  • Handed over to the MMV Access and Product Management team in May 2015 to help maximize patient access – read statement

ASAQ Press Pack, March 1st 2007


Read more about:
The Successful Development of a Fixed Dose Combination of ASAQ

The ASAQ Story


Key Scientific Publications

BMC Medicine, March 2015
The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data

Malaria Journal, December 2014
Fixed dose artesunate amodiaquine – a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine

Malaria Journal, March 2014
Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999–2009

Malaria Journal, July 2013
Efficacy of ASAQ and AL fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial 

Malaria Journal, July 2013
Tolerability and safety of ASAQ and AL fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia

Malaria Journal, July 2009
Randomized, multicentre assessment of the efficacy and safety of ASAQ – a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria



Implementation progress

Handed over to MMV Access team in 2015

More than 516 million treatments distributed

ASAQ registered in 32 countries & territories

Technology transfer to Zenufa (Tanzania)